# Rasburicase for Hyperuricemia

> **NCT00290992** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 30 (actual)

## Conditions studied

- Nutritional and Metabolic Diseases

## Interventions

- **DRUG:** rasburicase (SR29142)

## Key facts

- **NCT ID:** NCT00290992
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2009-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290992, "Rasburicase for Hyperuricemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00290992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*